Abstracts tagged "autoimmune diseases"

Abstract Number: 0991 • ACR Convergence 2020
Pathogenic, Glycolytic PD-1+ B Cells Accumulate in the Hypoxic RA Joint
Achilleas Floudas¹, Nuno Neto², Viviana Marzaioli³, Kieran Murray⁴, Barry Moran⁵, Michael Monaghan⁶, Candice Low⁷, Ronan Mullan⁸, Navin Rao⁹, Vinod Krishna⁹, Sunil Nagpal¹⁰, Douglas Veale¹¹ and Ursula Fearon³, ¹Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Dublin, Ireland, ²Department of Mechanical and Manufacturing Engineering, Dublin, Dublin, Ireland, ³Molecular Rheumatology, Trinity College Dublin, Dublin, Dublin, Ireland, ⁴Saint Vincent's University Hospital, Dublin 4, Dublin, Ireland, ⁵Trinity Biomedical Sciences Institute, Dublin, Ireland, ⁶Department of Mechanical and Manufacturing Engineering, Dublin, Ireland, ⁷EULAR Centre for Arthritis and Rheumatic diseases, St Vincents University Hospital, UCD, Dublin, Ireland, ⁸Adelaide and Meath Hospital, Dublin, Dublin, Ireland, ⁹Janssen R&D, Spring House, PA, ¹⁰Janssen Research & Development, Collegeville, PA, ¹¹EULAR Centre for Arthritis and Rheumatic Diseases, St Vincents University Hospital, UCD, Dublin, Dublin, Ireland
Background/Purpose: Rheumatoid arthritis (RA) often has a progressive and debilitating course, with significant impact on the patient’s quality of life. Despite the long-known association with…
Abstract Number: 1098 • ACR Convergence 2020
Anti-cortactin Autoantibodies Are Associated with Key Clinical Features in Adult Myositis but Are Rarely Present in Juvenile Myositis
Iago Pinal-Fernandez¹, Katherine Pak², Albert Gil-Vila³, Andres Baucells⁴, Benjamin Plotz⁵, Maria Casal-Dominguez⁶, Assia Derfoul⁷, Maria Angeles Martinez⁴, Albert Selva-O'Callaghan³, Sara Sabbagh⁸, Frederick W. Miller¹, Lisa G. Rider⁹, Lisa Christopher-Stine¹⁰ and Andrew Mammen⁶, ¹National Institutes of Health, Bethesda, MD, ²NIAMS, NIH, Bethesda, MD, ³Vall d’Hebron Hospital, Barcelona, Spain, ⁴Sant Pau Hospital, Barcelona, Spain, ⁵Division of Rheumatology, New York University Langone Health, New York, NY, ⁶NIH, Bethesda, MD, ⁷NIAMS, NIH, Bethesda, ⁸Division of Rheumatology, Department of Pediatrics, Medical College of Wisconsin, Washington, DC, ⁹Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Garrett Park, MD, ¹⁰Johns Hopkins University, Baltimore, MD
Background/Purpose: To define the prevalence and clinical phenotype of anti-cortactin autoantibodies in adult and juvenile myositis.Methods: In this longitudinal cohort study, anti-cortactin autoantibody tiers were…
Abstract Number: 1403 • ACR Convergence 2020
Differential Effect of Abatacept vs TNF Blockers, on the Frequency of Circulating Follicular Helper (Tfh) and Periperal Helper (Tph) T Cells in Rheumatoid Arthritis
María-José Santos-Bornez¹, Paula Fortea-Gordo¹, Laura Nuño¹, Alejandro Villalba¹, Diana Peiteado¹, Irene Monjo², Alejandro Balsa³ and Maria-Eugenia Miranda-Carus¹, ¹Hospital La Paz - IdiPAZ, Madrid, Spain, ²Rheumatology, La Paz University Hospital- IdiPAZ, Madrid, Spain, ³Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain
Background/Purpose: CXCR5+PD-1hi follicular helper (Tfh) and CXCR5-PD-1hi peripheral helper (Tph) T cells play an important role in the pathogenesis of Rheumatoid Arthritis (RA) by providing…
Abstract Number: 1568 • ACR Convergence 2020
Impact of the SARS-CoV-2 Pandemic on a Cohort of Patients with Rheumatic Complications of Immune Checkpoint Inhibitors: A Registry Survey Study
Nilasha Ghosh¹, Aidan Tirpack², Caroline Benson³, Gregory Vitone³, Karmela Kim Chan² and Anne Bass¹, ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York
Background/Purpose: It is not known whether cancer patients being treated with immune checkpoint inhibitors (ICI) and/or immunosuppression are more vulnerable to SARS-CoV-2 or more apt…
Abstract Number: 1838 • ACR Convergence 2020
Aerobic Exercise Improves Fatigue and Quality of Life in Women with Systemic Lupus Erythematosus (Preliminary Analysis)
Marquis Chapman¹, Sarthak Gupta¹, Jun Chu¹, Mohammad Naqi¹, Zerai Manna², Mir Ali Mazhar¹, Adam Munday¹, Marybeth Stockman¹, Anam Ahmad¹, Gayle McCrossin¹, Bart Drinkard¹, Lisa Chin¹, Mariana Kaplan³, Randall Keyser¹, Leighton Chan¹ and Sarfaraz Hasni², ¹National Institutes of Health, Bethesda, MD, ²Lupus Clinical Trials Unit, NIAMS/NIH, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease of female predominance. One of the most debilitating symptoms experienced by SLE-patients is persistent…
Abstract Number: 0100 • ACR Convergence 2020
Concordance Between the QuantiFERON-TB Gold In-Tube and Tuberculin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Rheumatic Diseases
Cristobal Pavez Perales¹, Ana Quiles Rocher², Elena Grau Garcia³, Marta De la Rubia Navarro¹, Samuel Leal Rodriguez⁴, Roxana Gonzalez Mazario¹, Jorge Juan Fragio Gil¹, Cristina Alcañiz Escandell³, Jose Ivorra Cortes¹, Inmaculada Chalmeta Verdejo¹, Luis Gonzalez Puig⁵, Isabel Martinez Cordellat¹, Rosa Negueroles Albuixech¹, Jose Eloy Oller Rodriguez¹, Francisco Miguel Ortiz Sanjuan⁴, Elvira Vicens Bernabeu⁴, Carmen Najera Herranz¹, Ines Canovas Olmos¹ and Jose Andres Roman Ivorra¹, ¹Rheumatology Department. HUP La Fe, Valencia, Spain, ²Medical School, UCV, Valencia, Valencia, Spain, ³Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁴Rheumatology Department, HUP La Fe, Valencia, Spain, ⁵Rheumatology Department. HUP La Fe, Torrente ( Valencia), Spain
Background/Purpose: Patients with rheumatic diseases (RD) are at higher risk of latent tuberculosis infection (LTBI) reactivation. To detect and treat it before starting treatment, especially with biological therapies, decrease the reactivation risk. Diagnosis is carried…
Abstract Number: 0465 • ACR Convergence 2020
The COVID-19 Pandemic and Its Effect on Patients with Chronic Rheumatologic Disease Regarding the Value of Vaccination Recommendations
Rebecca Overbury¹, Gregory Stoddard² and Tracy Frech³, ¹University of Utah and Primary Children's Hospital, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT
Background/Purpose: Vaccinations are an important component of care in rheumatology as many patients are immunocompromised by treatment therapies. Patients are sometimes reticent to receive recommended…
Abstract Number: 0636 • ACR Convergence 2020
Rheumatology Patient Experience and Trends During the SARS-COV-2 Pandemic
Cuoghi Edens¹, Kichul Ko¹ and Kimberly Trotter¹, ¹University of Chicago, Chicago, IL
Background/Purpose: Rheumatic disease patients are counseled on the immunosuppressive aspect of their rheumatic disease treatment and their increased risk of infection. Little is known about…
Abstract Number: 0992 • ACR Convergence 2020
Impact of Selective Inhibitors of Nuclear Export on SLE Plasma Cells Is Modulated by the BM Microenvironment
Neha Nandedkar-Kulkarni¹, Nida Meednu², Jennifer Albrecht², Jennifer Barnas², Douglas Widman³ and Jennifer Anolik², ¹University of Rochester, Rochester, NY, ²University of Rochester Medical center, Rochester, NY, ³Karyopharm Therapeutics, Newton, MA
Background/Purpose: Systemic lupus erythematous (SLE) is a complex autoimmune disorder with heterogeneous disease presentation and a multi-pronged pathogenesis. Although autoreactive plasma cells play a key…
Abstract Number: 1130 • ACR Convergence 2020
Patient Perspectives on Biobanking and Data-linkage for Rheumatic Disease Research
Abhishikta Dey¹, Marita Cross², Tom Lynch³, Carlos El-Haddad⁴ and Lyn March⁵, ¹NSW Rheumatology Advanced Trainee, Sydney, New South Wales, Australia, ²Institute of Bone and Joint Research, University of Sydney, Sydney, Australia, ³A3BC, Sydney, New South Wales, Australia, ⁴Liverpool Hospital, Sydney, Australia, ⁵Institute of Bone and Joint Research, University of Sydney, Sydney, New South Wales, Australia
Background/Purpose: The causes of arthritis and autoimmune conditions remain unknown. A complex interplay of genetic and environmental factors is thought to underlie these diseases. Prospective…
Abstract Number: 1404 • ACR Convergence 2020
Investigating the Dermatomyositis Skin Inflammatory Infiltrate Using Image Mass Cytometry
Jay Patel¹, Spandana Maddukuri², Yubin Li³, Christina Bax⁴ and Victoria Werth³, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, ²University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Montville, NJ, ³University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ⁴University of Pennsylvania, Department of Dermatology, Philadelphia
Background/Purpose: Dermatomyositis (DM) is a systemic autoimmune disease affecting the skin and muscles, among other organs. The inflammatory infiltrate in skin has not been fully…
Abstract Number: 1569 • ACR Convergence 2020
Immune Related Adverse Events Related to Check Point Inhibitors Among Outpatients in an Academic Center
Bushra Akram¹, Aleena Itani¹, Mohammad Razaq², Samera Vaseer¹, Sara Vesely¹ and Pawan Acharya¹, ¹University of Oklahoma Health Sciences Center, Oklahoma City, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Immune check point inhibitors (ICIs) allow the body to recognize tumor cells as non-self, resulting in immune-cell mediated tumor cell destruction. These therapies have the…
Abstract Number: 1843 • ACR Convergence 2020
Integrated Efficacy of the AURORA 1 and AURA-LV Trials Confirms Voclosporin Rapid Proteinurea Reduction in the Presence of Low-Dose Steroids
Ellen M Ginzler¹, Joshua Kaplan², Laura Lisk³, Ray Federico⁴, Neil Solomons⁵ and Robert Huizinga⁵, ¹SUNY Downstate Health Sciences University, Brooklyn, ²Rutgers University, New Brunswick, NJ, ³Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, ⁴Aurinia Pharmaceuticals, Inc., Victoria, Canada, ⁵Aurinia Pharmaceuticals, Victoria, BC, Canada
Background/Purpose: Voclosporin (VCS) is a novel calcineurin inhibitor (CNI) with a favorable metabolic profile and a consistent predictable dose response potentially eliminating the need for…
Abstract Number: 0129 • ACR Convergence 2020
Glucocorticoid-Induced Osteoporosis in Patients with Chronic Inflammatory Rheumatic Diseases: A Multivariate Linear Regression Analysis Identifying Factors Affecting Bone Mineral Density
Edgar Wiebe¹, Desiree Freier¹, Dörte Huscher², Sandra Hermann¹, Robert Biesen³ and Frank Buttgereit⁴, ¹Charité University Medicine Berlin, Dep. of Rheumatology and Clinical Immunology, Berlin, Germany, ²Charité University Medicine Berlin, Dep. of Biometry and Clinical Epidemiology, Berlin, Germany, ³Charité University Medicine, Dep. of Rheumatology and Clinical Immunology, Berlin, ⁴Charité University Medicine, Berlin, Germany
Background/Purpose: Rheumatic diseases are associated with increased systemic bone loss and fracture risk related to chronic inflammation, disease-specific, general and demographic risk factors as well…
Abstract Number: 0468 • ACR Convergence 2020
Concerns and Health-Related Behaviors During the COVID-19 Pandemic in Patients with or Without Autoimmune Rheumatic Disease in a Large Physician Network
Michael George¹, Shilpa Venkatachalam², Shubhasree Banerjee¹, Joshua Baker¹, Peter Merkel¹, David Curtis³, Kelly Gavigan⁴, Maria (Maio) Danila⁵, Daniel Kirby⁶, George Munoz⁷, William Sunshine⁸, William Nowell⁹ and Jeffrey R Curtis¹⁰, ¹University of Pennsylvania, Philadelphia, PA, ²Global Healthy Living Foundation, Upper Nyack, ³Global Healthy Living Foundation, New York City, ⁴Global Healthy Living Foundation, Upper Nyack, NY, ⁵University of Alabama at Birmingham (UAB), Birmingham, AL, ⁶AARA, Charlotte, NC, ⁷AARA, Aventura, FL, ⁸AARA, Boca Raton, FL, ⁹Global Healthy Living Foundation, New York City, NY, ¹⁰Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patients with autoimmune rheumatic diseases (ARD) may be particularly concerned about COVID-19. We aimed to compare concerns and health-related behaviors of patients with common…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].